Previous Close | N/A |
YTD Return | N/A |
Expense Ratio (net) | N/A |
Category | N/A |
Last Cap Gain | N/A |
Morningstar Rating | N/A |
Morningstar Risk Rating | N/A |
Sustainability Rating | N/A |
Net Assets | N/A |
Beta (5Y Monthly) | N/A |
Yield | N/A |
5y Average Return | N/A |
Holdings Turnover | N/A |
Last Dividend | N/A |
Average for Category | N/A |
Inception Date | N/A |
Spanish pharmaceutical company Rovi said on Thursday it had hired financial advisory and asset management firm Lazard to explore the sale of its third-party manufacturing business that it uses to make COVID vaccines. Madrid-based Rovi said it regularly assesses potential strategic alternatives to maximise value and decided to hire Lazard, although no specific decision had been taken and the analysis was still ongoing.